Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC).Xīn Gào, Daniel P. Petrylak, Jacqueline Vuky et al.|Journal of Clinical Oncology|2022Cited by 192